Ocrelizumab in PPMS
Research payments
$3,282,462
Through program year 2023, $3,282,462 in research payments was reported against Ocrelizumab in PPMS, across 1,125 payments.
- Paid by (largest first)
- Roche Products Limited; Hoffmann-La Roche Limited
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $989 | 5 |
| 2022 | Research | $1,008,451 | 301 |
| 2021 | Research | $655,337 | 267 |
| 2020 | Research | $757,321 | 248 |
| 2019 | Research | $860,364 | 304 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
6 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stuart Shafer Vero Beach, FL Named on 245 payments
- Emmanuelle Waubant San Francisco, CA Named on 103 payments
- Corey Ford Albuquerque, NM Named on 39 payments
- Mary Ann Picone Teaneck, NJ Named on 37 payments
- Anne Cross Saint Louis, MO Named on 34 payments
- Martin Belkin Farmington Hills, MI Named on 33 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.